ImmunityBio (IBRX) Change in Cash (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Change in Cash data on file, last reported at $117.0 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 241.41% year-over-year to $117.0 million in Q1 2026; TTM through Mar 2026 was $145.3 million, a 301.21% increase from a year earlier, with the FY2025 full-year figure at -$54.5 million, up 55.3% from the prior year.
• Change in Cash for Q1 2026 stood at $117.0 million, up from $28.1 million in the prior quarter.
• Over the last five years, Change in Cash for IBRX reached as high as $134.5 million in Q3 2023 and fell as low as -$144.7 million in Q1 2022.
• Historically, Change in Cash has averaged $1.5 million across 5 years, with a median of $480000.0 in 2022.
• Across the five-year window, Change in Cash sank 1582.14% in 2022 and jumped 18127.08% in 2023, its largest moves.
• Year by year, Change in Cash stood at $480000.0 in 2022, then soared by 18127.08% to $87.5 million in 2023, then slumped by 63.87% to $31.6 million in 2024, then decreased by 11.13% to $28.1 million in 2025, then surged by 316.6% to $117.0 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $117.0 million in Q1 2026, $28.1 million in Q4 2025, and -$76.8 million in Q3 2025.